Becton Dickinson Raises Annual Guidance Following 5.4% Q3 Revenue Growth

Key Facts

Amid sustained demand for innovative healthcare solutions, Becton Dickinson announced strong financial results for its fiscal third quarter ending June 30, 2026. The company reported revenue of $5.0 billion, representing a 5.4% year-over-year increase, driven by continued business momentum in the medical technology sector. Following these results, the company raised the midpoint of its adjusted diluted EPS guidance for the full fiscal year.

The financial data reflects a significant improvement in operational efficiency, with the company's free cash flow increasing 44.6% to reach $1.7 billion year-to-date. Per market data, this performance comes as investors monitor margin stability in the medical device sector, particularly as the company recorded charges related to legal matters and product remediation over the past nine months.

At the close on August 5, 2026, BDX shares stood at $170.66, with a daily trading range between $168.01 and $170.91. Looking at the economic calendar, there are no direct upcoming catalysts for the company in the next seven days; however, markets will continue to monitor the impact of global inflation trends on production costs within the healthcare sector.